Congrats to all those investors in CLRT and BioMedReports for writing up the company last month.
NGNM is another cancer diagnostics company that i've been following and worth a real hard look at these levels. They've got a great management team lead by CEO Van Oort, the former COO of Quest Diagnostics and Covance who wrote his own $500,000 check to join the company back in March 2009. Abbott Labs (ABT) also invested $4.8 million in July 2009, at $1.36 per share, and is a 10% shareholder.
NGNM continues to growth the business and on pace to generate around $35 million in sales this year. With new cancer tests coming to market and a great relationship with ABT, NGNM is undervalued and well positioned.
At 5x sales, which is what GE just paid for CLRT, NGNM would fetch $4-5 per share.
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM